Oncology · Small molecule (oral, once daily)

Daraxonrasib (Rasonque)

Daraxonrasib (Rasonque) is an oral RAS inhibitor approved by the FDA in August 2026 for metastatic pancreatic cancer. In the 500-patient RASolute 302 trial, median overall survival was 13.2 months versus 6.7 months with chemotherapy.

FDA-approvedFDA-approved August 26, 2026 for previously treated metastatic pancreatic cancer after roughly doubling survival in Phase 3

FDA-approved: Approved by the FDA for at least one use. Other uses may still be in clinical trials. About status badges

FDA: approved as RASONQUE (NDA220910), original approval Aug 26, 2026. Approval covers specific uses only; see programs below.

DeveloperRevolution Medicines
Drug typeSmall molecule (oral, once daily)
TargetRAS proteins (KRAS, NRAS, HRAS) in their active state
MechanismInhibits the active, 'ON' form of RAS proteins across multiple RAS mutations, shutting down a signal that drives tumor growth
Other namesRMC-6236

Key points

  • RAS genes are mutated in most pancreatic cancers and were long considered 'undruggable'. Daraxonrasib inhibits active RAS across multiple mutation types.
  • In the Phase 3 RASolute 302 trial (500 patients), median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy (hazard ratio 0.40).
  • The FDA approved it on August 26, 2026, about 6.5 months ahead of its goal date, under the National Priority Voucher pilot and Real-Time Oncology Review.
  • Side effects are common: rash, diarrhea, and mouth sores were frequent in earlier trials, and the label carries warnings for skin toxicity, stomatitis, and diarrhea.
  • Phase 3 trials are testing it earlier in pancreatic cancer and in RAS-mutant lung cancer.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Pancreatic cancer
Approved for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy (FDA). RASolute 303, 304, and 309 test other settings (registry).
Approved (FDA, August 26, 2026); further Phase 3 trials14
13 active · 0 completed
Not shown (see note)
Non-small cell lung cancer
RASolve 301 in RAS-mutant non-small cell lung cancer is recruiting (registry).
Phase 33
3 active · 0 completed
52.4% eventual approval
Phase 3 → application: 57.8%
Other RAS-mutant cancers
Early studies in other RAS-mutant cancers (registry).
Phase 1/24
4 active · 0 completed
7.9% eventual approval
Phase 1 → Phase 2: 52%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What daraxonrasib is

Daraxonrasib is an oral drug developed by Revolution Medicines that inhibits RAS proteins in their active, signal-sending ("ON") state. RAS proteins act like switches that tell cells to grow. Mutations can lock them on, and RAS mutations drive most pancreatic cancers as well as many lung and colorectal cancers.

For decades RAS was considered "undruggable" because its surface offered few places for a drug to bind. Earlier approved RAS drugs target a single mutation, KRAS G12C, which is uncommon in pancreatic cancer. Daraxonrasib is designed to act across multiple RAS mutations, which is why it matters so much for pancreatic cancer. See What Are Genetic Mutations?

Clinical evidence

Phase 1/2

In the Phase 1/2 study published in the New England Journal of Medicine in 2026, 168 patients with pancreatic cancer received daraxonrasib at 300 mg or less:

  • Among 26 patients with RAS G12 mutations treated second-line at 300 mg, 35% had an objective response. Median progression-free survival was 8.5 months and median overall survival 13.1 months.
  • Treatment-related adverse events occurred in 96% of patients and were grade 3 or higher in 30%. The most common were rash, diarrhea, nausea, mouth sores, vomiting, and fatigue.

Phase 3: RASolute 302

Measure Daraxonrasib Standard chemotherapy
Patients randomized 500 in total (1:1)
Median overall survival 13.2 months 6.7 months
Overall survival hazard ratio 0.40 (95% CI 0.30–0.53)
Median progression-free survival 7.2 months 3.6 months
Progression-free survival hazard ratio 0.49 (95% CI 0.38–0.64)

Source: FDA approval announcement, August 26, 2026.

A hazard ratio of 0.40 means a 60% lower risk of death at any point during follow-up. That is an unusually large effect for metastatic pancreatic cancer, where treatment advances are typically measured in weeks.

Regulatory status

The FDA approved Rasonque (daraxonrasib) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. According to the FDA:

  • the recommended dose is 300 mg once daily by mouth,
  • the drug had Breakthrough Therapy and Orphan Drug designations,
  • the application was reviewed under the Commissioner's National Priority Voucher pilot and the Real-Time Oncology Review pilot, and
  • it was approved about 6.5 months ahead of the FDA goal date.

The label includes warnings for skin and soft-tissue toxicity, mouth inflammation, diarrhea, gastrointestinal perforation, lung inflammation, and harm to a developing fetus. Revolution Medicines has also announced European Commission approval (company-reported).

Scientific perspective

Daraxonrasib supports a theme in modern oncology: drugs aimed at a validated genetic driver can work dramatically better than conventional therapy. Here, the driver is present in most pancreatic tumors, so the potential reach is broad. The approval rests on a randomized Phase 3 trial with overall survival as a measure, the strongest kind of evidence, which contrasts with programs relying on progression-free survival alone.

Development perspective

  • Approved use: previously treated metastatic pancreatic cancer. No benchmark is shown for an approved program.
  • Expansion: Phase 3 trials in earlier-line pancreatic cancer and in RAS-mutant lung cancer could substantially widen its use.
  • Tolerability: frequent skin, mouth, and gastrointestinal side effects will shape how it is used in practice.

Development timeline

  1. May 7, 2026Phase 1/2 results published: 35% response rate and 13.1-month median overall survival in second-line RAS G12-mutant pancreatic cancer at 300 mg. Peer-reviewed
  2. Jun 2026RASolute 302 Phase 3 trial reaches primary completion (estimated in the registry). Registry
  3. Aug 26, 2026FDA approves Rasonque (daraxonrasib) for previously treated metastatic pancreatic adenocarcinoma: overall survival 13.2 vs 6.7 months (HR 0.40). Regulator

What could change the outlook

  • Results of RASolute 303, 304, and 309, which test daraxonrasib in other pancreatic cancer settings, including earlier treatment.
  • RASolve 301 in RAS-mutant lung cancer, which could extend use beyond pancreatic cancer.
  • Real-world tolerability, since skin, mouth, and gastrointestinal side effects were common in trials.
  • Combination studies, including a collaboration with Summit's ivonescimab mentioned in Summit's disclosures.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Daraxonrasib. Company-reported, not independently verified.

  1. RegulatoryCompany-reportedNov 16, 2026

    Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Complete Response Letter Received from FDA for BLA

    Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally...

    Company
    Summit Therapeutics Inc.
    Source
    SEC Form 8-K · Other events
  2. Quarterly reportCompany-reportedNov 4, 2026

    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and...

    The company will continue to provide more details in the coming months with respect to additional Phase III studies evaluating ivonescimab beyond NSCLC, CRC, UC, RCC, BTC, and head and neck squamous cell carcinoma (HNSCC). • In addition to the multiregional studies conducted and sponsored by Summit, Akeso is...

    Company
    Summit Therapeutics Inc.
    Source
    SEC Form 8-K · Financial results
  3. Quarterly reportCompany-reportedNov 4, 2026

    Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

    “The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union,” said Mark A.

    Company
    Revolution Medicines, Inc.
    Source
    SEC Form 8-K · Financial results

All Daraxonrasib disclosures in Pipeline News

Clinical trials

22 registered trials list Daraxonrasib as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Pancreatic cancer

TrialPhaseStatusEnrollmentPrimary completionResults posted
RASolute 303 · NCT07491445
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 3Recruiting900 (est.)Apr 2028 (est.)No
RASolute 302 · NCT06625320
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3Active, not recruiting500Jun 2026 (est.)No
RASolute 304 · NCT07252232
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3Recruiting500 (est.)May 10, 2029 (est.)No
RASolute 309 · NCT07805954
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Phase 3Recruiting400 (est.)Mar 2029 (est.)No
NCT06445062
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/2Recruiting1,130 (est.)Sep 30, 2028 (est.)No
NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/2Recruiting754 (est.)May 31, 2027 (est.)No
NCT06128551
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Phase 1/2Recruiting534 (est.)Dec 2028 (est.)No
NCT06922591
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Phase 1/2Recruiting183 (est.)Jun 2027 (est.)No
6 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06040541
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1Recruiting604 (est.)Dec 31, 2026 (est.)No
NCT07349537
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1Recruiting574 (est.)Apr 2028 (est.)No
MTAPESTRY 103 · NCT06360354
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Phase 1Active, not recruiting120Oct 31, 2026 (est.)No
NCT07756281
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
Phase 1Recruiting40 (est.)Jun 1, 2029 (est.)No
NCT07898813
Daraxonrasib in Resectable PDAC
Phase 1Not yet recruiting30 (est.)Feb 17, 2029 (est.)No
NCT07573215
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
N/AAPPROVED_FOR_MARKETING——No

Non-small cell lung cancer

TrialPhaseStatusEnrollmentPrimary completionResults posted
RASolve 301 · NCT06881784
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3Recruiting590 (est.)Dec 1, 2027 (est.)No
NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2Recruiting616 (est.)Jun 2027 (est.)No
NCT07397338
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2Recruiting370 (est.)May 2029 (est.)No

Other RAS-mutant cancers

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07492680
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Phase 2Recruiting254 (est.)Aug 15, 2028 (est.)No
NCT07819838
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
Phase 1/2Not yet recruiting77 (est.)Apr 9, 2032 (est.)No
NCT07793253
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Phase 2Not yet recruiting55 (est.)Nov 2030 (est.)No
NCT07908550
Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer
Phase 2Not yet recruiting55 (est.)Dec 2029 (est.)No

Clinical pharmacology and supporting studies

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07895498
A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer
Phase 2Recruiting122 (est.)Oct 16, 2028 (est.)No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. U.S. Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma (August 26, 2026).Regulator
  2. Wolpin BM, et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. New England Journal of Medicine. 2026;394(18):1790–1802.Peer-reviewed
  3. ClinicalTrials.gov. RASolute 302 (NCT06625320).Registry
  4. Revolution Medicines. U.S. FDA approves Rasonque (daraxonrasib) in metastatic pancreatic cancer.Company-reported
  5. Revolution Medicines. European Commission approves Rasonque (daraxonrasib).Company-reported
  6. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.